Our latest webinar starts on Tuesday 26 January at 18:00. We are joined by guest speakers from Orosur Mining, Savannah Resources, Rainbow Rare Earths and Goldplat. Register here.

Less Ads, More Data, More Tools Register for FREE
Hardman Healthcare Index - Life Sciences, where the smart money was in an 'exceptional' 2020
Hardman Healthcare Index - Life Sciences, where the smart money was in an 'exceptional' 2020View Video

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 170.00
Bid: 167.00
Ask: 168.00
Change: 1.00 (0.59%)
Spread: 1.00 (0.60%)
Open: 170.00
High: 176.00
Low: 167.00
Yest. Close: 169.00
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

20 Jan 21 21:16

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

13 Jan 21 10:24

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

11 Jan 21 20:54

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

18 Dec 20 12:08

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

18 Dec 20 11:06

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

18 Dec 20 10:29

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

18 Nov 20 13:59

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

13 Nov 20 14:28

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

13 Nov 20 10:24

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

2 Nov 20 20:03

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

15 Oct 20 11:39

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

14 Oct 20 18:02

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

29 Sep 20 12:14

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

9 Sep 20 16:04

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

9 Sep 20 12:23

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.